Compare EVMN & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVMN | GAIN |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.9M | 551.1M |
| IPO Year | 2025 | 2005 |
| Metric | EVMN | GAIN |
|---|---|---|
| Price | $21.90 | $13.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $39.33 | $14.50 |
| AVG Volume (30 Days) | 92.4K | ★ 118.6K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | ★ 15.76% |
| EPS Growth | N/A | ★ 135.24 |
| EPS | N/A | ★ 2.49 |
| Revenue | $3,000,000.00 | ★ $97,742,000.00 |
| Revenue This Year | N/A | $7.46 |
| Revenue Next Year | N/A | $5.05 |
| P/E Ratio | ★ N/A | $5.60 |
| Revenue Growth | ★ 40.00 | 6.86 |
| 52 Week Low | $16.70 | $11.42 |
| 52 Week High | $24.03 | $15.34 |
| Indicator | EVMN | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.19 |
| Support Level | N/A | $13.83 |
| Resistance Level | N/A | $14.04 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 79.25 |
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.